BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 38450598)

  • 1. AGC1-mediated Metabolic Reprogramming and Autophagy Sustain Survival of Hepatocellular Carcinoma Cells under Glutamine Deprivation.
    Liu Y; Miao Z; Yang Q
    Cell Biochem Biophys; 2024 May; ():. PubMed ID: 38789662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research progress in the metabolic reprogramming of hepatocellular carcinoma (Review).
    Gao W; Wang J; Xu Y; Yu H; Yi S; Bai C; Cong Q; Zhu Y
    Mol Med Rep; 2024 Jul; 30(1):. PubMed ID: 38818815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tRNA Gm18 methyltransferase TARBP1 promotes hepatocellular carcinoma progression via metabolic reprogramming of glutamine.
    Shi X; Zhang Y; Wang Y; Wang J; Gao Y; Wang R; Wang L; Xiong M; Cao Y; Ou N; Liu Q; Ma H; Cai J; Chen H
    Cell Death Differ; 2024 Jun; ():. PubMed ID: 38867004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of lipid metabolism in hepatocellular carcinoma.
    Cheng Y; He J; Zuo B; He Y
    Discov Oncol; 2024 Jun; 15(1):206. PubMed ID: 38833109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFRD1 promotes tumor cells "low-cost" survival under glutamine starvation via inhibiting histone H1.0 nucleophagy.
    Huang Y; Meng F; Zeng T; Thorne RF; He L; Zha Q; Li H; Liu H; Lang C; Xiong W; Pan S; Yin D; Wu M; Sun X; Liu L
    Cell Discov; 2024 May; 10(1):57. PubMed ID: 38802351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamine metabolic reprogramming in hepatocellular carcinoma.
    Ye Y; Yu B; Wang H; Yi F
    Front Mol Biosci; 2023; 10():1242059. PubMed ID: 37635935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA
    Jiang J; Dong W; Zhang W; Wang Q; Wang R; Wang J; Wu H; Dong H; Zhao RC; Wang J; Li Z
    Discov Med; 2023 Dec; 35(179):995-1014. PubMed ID: 38058065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
    J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discoidin domain receptor 1 promotes hepatocellular carcinoma progression through modulation of SLC1A5 and the mTORC1 signaling pathway.
    Pan Y; Han M; Zhang X; He Y; Yuan C; Xiong Y; Li X; Zeng C; Lu K; Zhu H; Lu X; Liu Q; Liang H; Liao Z; Ding Z; Zhang Z; Chen X; Zhang W; Zhang B
    Cell Oncol (Dordr); 2022 Feb; 45(1):163-178. PubMed ID: 35089546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells.
    Yoo HC; Park SJ; Nam M; Kang J; Kim K; Yeo JH; Kim JK; Heo Y; Lee HS; Lee MY; Lee CW; Kang JS; Kim YH; Lee J; Choi J; Hwang GS; Bang S; Han JM
    Cell Metab; 2020 Feb; 31(2):267-283.e12. PubMed ID: 31866442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Zhang Q; Wei T; Jin W; Yan L; Shi L; Zhu S; Bai Y; Zeng Y; Yin Z; Yang J; Zhang W; Wu M; Zhang Y; Peng G; Roessler S; Liu L
    J Hepatol; 2024 Feb; 80(2):293-308. PubMed ID: 38450598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.
    Du D; Liu C; Qin M; Zhang X; Xi T; Yuan S; Hao H; Xiong J
    Acta Pharm Sin B; 2022 Feb; 12(2):558-580. PubMed ID: 35256934
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.